FDC launches 2 variants of Favipiravir in India at Rs 55 per tablet
Team Udayavani, Aug 25, 2020, 6:59 PM IST
New Delhi: Drug firm FDC Ltd on Tuesday said it has launched two variants of the COVID-19 drug Favipiravir under the brand names PiFLU and Favenza.
The Drug Controller General of India (DCGI) had earlier approved the use of Favipiravir, an off patent, oral antiviral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms, FDC said in a statement.
“Early diagnosis and treatment will help in arresting the deteriorating condition of patients, and we will be working with the government and healthcare fraternity to make Favenza and PiFLU available across the country” FDC spokesperson Mayank Tikkha said.
Both the products are currently available across the country, the company said.
The price per tablet is Rs 55 for both the variants, it added.
Shares of FDC Ltd closed at Rs 317.50 per scrip on BSE, down 1.17 per cent over previous close.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Air pollution: SC flags Delhi govt’s failure to implement GRAP-4 curbs on entry of trucks
Baba Siddique murder: Man held from Akola, 26th arrest in case
SC notice to Gyanvapi mosque committee on plea for ASI survey of ‘shivling’ area
Delhi court stays defamation case against CM Atishi
Sambhal Jama Masjid row: Friday prayers held peacefully amid tight security
MUST WATCH
Latest Additions
Air pollution: SC flags Delhi govt’s failure to implement GRAP-4 curbs on entry of trucks
Drugs worth Rs 6 crore seized in Bengaluru, five arrested
Siddaramaiah urges Nirmala Sitharaman to address NABARD’s loan cuts to farmers
Satwik-Chirag enter semifinals, Lakshya loses to Antonsen in China Masters
BJP stages protest against Congress govt in Karnataka over Waqf properties row
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.